A sponsor-investigator initiates a study and personally conducts it. That makes you responsible for the duties of a sponsor and of an investigator at once. This guide explains the role, the duties under FDA rules, who should and should not take it on, and the steps to get set up. General information, not legal advice.
Free sandbox · No credit card · 21 CFR Part 11 aligned
Study
Investigator-initiated, Phase 2
Role
PI is sponsor-investigator
Open items
4
The role in brief
The role
In most drug trials two parties share the regulatory load. The sponsor, usually a company, holds the IND, funds and oversees the study. The investigator, at a clinical site, runs it on the ground. In an investigator-initiated trial the clinician or academic who had the idea may run it without any company, so one person ends up holding both roles. That person is the sponsor-investigator.
You become one by choosing to submit and hold the IND (or equivalent) in your own name and to conduct the study personally. If a university or hospital acts as sponsor and you only serve as PI, you are an investigator, not a sponsor-investigator. If a company sponsors and you only run a site, the same. The label changes your duties materially, which is why it deserves an explicit decision at the start. Our guide to the FDA IND application for academics covers the filing; the investigator-initiated trial startup checklist covers the first months.
Device and non-drug research use related but different rules (21 CFR Part 812 for investigational devices, for example) and outside the US the sponsor concept differs, with national laws and the EU Clinical Trials Regulation setting their own sponsor duties. This page focuses on FDA drug and biologic IND practice. Check the rules that apply in your country and for your product type.
Responsibilities
Regulation references are for orientation. Check the current text on eCFR and your institution's policy, which is often stricter.
| Area | What it means for you | Where to look |
|---|---|---|
| IND filing | Prepare and submit the IND with Form FDA 1571, protocol, investigator information, chemistry and nonclinical data or cross-references. Do not start before the waiting period unless FDA says you may. | 21 CFR 312.23; Form FDA 1571 |
| IRB oversight | Obtain IRB approval before enrolment, report changes and progress, and keep records of review. | 21 CFR Part 56 |
| Informed consent | Ensure each participant gives informed consent in line with FDA rules. See electronic consent regulations. | 21 CFR Part 50 |
| Investigator duties | Follow the protocol, control the drug, keep case histories, supervise delegates and keep a delegation record. | 21 CFR 312.60 onward; Form FDA 1572 where required |
| Monitoring | Make sure the investigation is monitored. Independence is advisable, since you cannot monitor yourself credibly. | 21 CFR 312.50, 312.56; risk-based monitoring |
| Safety reporting | Review safety information and report qualifying events to FDA and investigators within the deadlines the rule sets. Know them before the first dose. | 21 CFR 312.32 |
| Annual and other reports | Submit annual progress reports, amendments and, where applicable, withdrawal or termination notices. | 21 CFR 312.30, 312.33 |
| Records and retention | Keep drug disposition, case histories and sponsor records for the required period. | 21 CFR 312.57, 312.62; retention guide |
| Financial disclosure | Collect and handle financial interest information of investigators where required. | 21 CFR Part 54 (check applicability) |
| Registration and results | Check whether the trial must be registered and results reported, and who the responsible party is. | ClinicalTrials.gov rules; check current requirements |
This table summarises duties in general terms from FDA regulations and university HRPP checklists. Confirm every item with your regulatory office. Not legal advice.
The decision
The strongest reason to become a sponsor-investigator is control: you own the question, the design and the timeline, without a company deciding priorities. The strongest reason not to is workload and exposure. A sponsor-investigator is inspected as a sponsor and as an investigator, held to the same standards as a corporate sponsor, with a fraction of the staff.
You have institutional backing, a research office that will review the IND, a statistician, a pharmacy and a named person for regulatory affairs. You have budget for independent monitoring and a data system. You can name who covers safety review when you are in clinic or away.
You are planning to do monitoring, safety review and data cleaning on your own after clinic hours; you have not discussed the IND with your institution; the product is novel with substantial unknowns; or the study has multiple sites that will each need oversight. In those cases a CRO, a co-sponsor arrangement or an institution acting as sponsor may fit better. See how to run a trial without a CRO for an honest view of what you can and cannot do alone, and how to choose a CRO when you decide to delegate.
The path
Order matters. Steps one to three decide whether the rest is needed; steps four to eight make it compliant and workable.
The research office, sponsored programs and the IRB often have a sponsor-investigator policy, insurance requirements and templates. Many institutions require sign-off before you contact FDA.
Review the exemption criteria in 21 CFR 312.2 for your drug, population and purpose. Where unsure, ask FDA through a pre-IND meeting or request. Record the decision in writing either way.
Write the protocol, with an honest risk assessment, using a protocol template or how to write a clinical trial protocol.
Assemble the application, Form FDA 1571 and supporting data. The IND guide for academics walks through it. Wait for the review period or the go-ahead.
Appoint an independent monitor, write the monitoring plan, define the safety review process and decide whether a data safety monitoring board is needed. Use the monitoring visit report template as a starting point.
Write requirements, choose a system with audit trail, access control and signatures that suit your regulator, and run UAT. See the URS template and EDC for investigator-initiated trials.
Create the investigator site file and the sponsor file, a delegation log, training records and a trial master file so nothing is reconstructed later.
File safety reports and annual reports on time, track deviations, keep records, and plan the archive before the last visit.
Of the eight steps, the data system is the one you can finish in an afternoon. Build your study in the free sandbox, with forms, edit checks, roles, e-signatures and an audit trail, and see what a lean sponsor-investigator setup looks like before you commit.
What you do in Capture
Capture is a self-serve, all-in-one clinical trial platform. It does not replace your regulatory duties, but it covers the data side with 21 CFR Part 11-aligned controls so you can focus on the rest.
IND decision and IRB approval
Documented
Build study and test in sandbox
Forms, checks, roles
Go live with first participants
Consent, then screen
Monitor, review safety, reconcile
Independent monitor
Lock, export, archive
Retention plan
What goes wrong
Inspections of investigator-initiated studies tend to find the same things. Safety reports submitted late because nobody owned the clock. Monitoring that existed only on paper or was done by the study coordinator who also entered the data. Delegation logs that did not match who actually did the work. Consent forms signed on the wrong version. Records that could not be found when asked. Each is a planning failure, not a knowledge failure, which is why a one-page responsibility matrix at the start is worth the hour it takes.
Use the matrix to assign every duty in the table above to a named person and a backup, then review it at each amendment. Pair it with the FDA inspection checklist and the protocol deviation tracking approach so problems are visible before an inspector sees them.
Under FDA's IND regulation, a sponsor-investigator is an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. A corporation or agency cannot be a sponsor-investigator. The person carries the duties of both sponsor and investigator.
No. Some investigations are exempt from the IND requirements, depending on the drug, the population and the purpose. The exemption criteria are in 21 CFR 312.2. Document the decision and confirm it with your institution or FDA.
The IND cover sheet is Form FDA 1571. Form FDA 1572, the Statement of Investigator, is required for investigators participating in an IND study; whether a sponsor-investigator also files one for their own IND is handled differently by institutions, so confirm locally.
The sponsor must ensure monitoring. Because you cannot credibly monitor your own work, most institutions require someone independent, such as a research office monitor or a contracted monitor. Document the plan.
Yes. You can delegate tasks to a CRO or vendors, but regulatory accountability stays with you. Transfer of obligations should be written down.
One with audit trail, access control, electronic signatures and exports that fit your regulator, and that a small team can set up without programmers. Capture offers 21 CFR Part 11-aligned controls and a free sandbox for building and testing before go-live.
No. It is a general summary. Check current regulations, institutional policy and, where needed, ask FDA or a regulatory adviser.
Keep exploring
FDA IND application guide for academics
Filing the IND.
Investigator-initiated trial startup checklist
The first months.
EDC for investigator-initiated trials
Data system for IITs.
Software for investigator-initiated trials
Tools for lean teams.
How to run a clinical trial without a CRO
What you can do alone.
How to set up a trial master file
Sponsor documents.
IRB submission checklist
What the IRB needs.
Good clinical practice
The standard you follow.
Free sandbox with every feature. No credit card, and you pay only when you go live with real participants.